The DOI matches its Crossref record; 134 of the 136 references it cites were found in a registry or an index.
Tumor-Associated Macrophages: From Mechanisms to Therapy
Open accessAbstract
The tumor microenvironment is a complex ecology of cells that evolves with and provides support to tumor cells during the transition to malignancy. Among the innate and adaptive immune cells recruited to the tumor site, macrophages are particularly abundant and are present at all stages of tumor progression. Clinical studies and experimental mouse models indicate that these macrophages generally play a protumoral role. In the primary tumor, macrophages can stimulate angiogenesis and enhance tumor cell invasion, motility, and intravasation. During monocytes and/or metastasis, macrophages prime the premetastatic site and promote tumor cell extravasation, survival, and persistent growth. Macrophages are also immunosuppressive, preventing tumor cell attack by natural killer and T cells during tumor progression and after recovery from chemo- or immunotherapy. Therapeutic success in targeting these protumoral roles in preclinical models and in early clinical trials suggests that macrophages are attractive targets as part of combination therapy in cancer treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Accordingly, TAM-based therapeutic strategies are being developed that aim at TAM targeting, TAM re-education, and TAM depletion [88, 96, 101, 102].”
From Tumor microenvironment complexity and therapeutic implications at a glance (2020) · cites this paper as [88]
The cited source says what the claim attributes to it.
In the citing paper
“Many therapy strategies have attempted to alter the polarization of macrophages’ “re-programming” or prevent monocyte tumor infiltration (Noy and Pollard, 2014).”
From Sysrev: A FAIR Platform for Data Curation and Systematic Evidence Review (2021) · cites this paper as Noy and Pollard, 2014
In the citing paper
“In preclinical models, both of these innate immune cell types aid tumor growth and metastasis through their secretion of factors that suppress antitumor immune responses, especially those of CD8 + T cells and NK cells (166, 167).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [167]
In the citing paper
“The production of colony stimulating factor 1 (CSF-1; also known as macrophage colony stimulating factor) by BCCs, has been reported to stimulate the recruitment of macrophages to primary breast tumors, leading to the secretion by tumor-associated macrophages (TAMs) of epidermal growth factor, which binds to its cognate receptor on BCCs to stimulate invasion and metastasis [36–38].”
From The hypoxic tumor microenvironment: A driving force for breast cancer progression (2016) · cites this paper as [38]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Forget, M. A., Voorhees, J. L., Cole, S. L., Dakhlallah, D. A., Patterson, I. L., Gross, A. C., Moldovan, L., Mo, X. M., Evans, R., Marsh, C. B., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0098623 · Cited by 79 · cited 2×
“Interestingly, CSF1 upregulates TIE2 on TAMs (Forget et al., 2014) indicating a link between CSF1, TIE2 macrophages, and the induction of the angiogenic switch.”
BackgroundRetractedHallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · cited 1×
“…the ways in which the microenvironmental support to tumors is the acquisition of a vasculature that provides oxygenation, as well as the nutrition and waste disposal required for growth above a certain size in a process often referred to as the ‘‘angiogenic switch’’ (Hanahan and Weinberg, 2011).”
BackgroundCoussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111 · cited 1×
“Furthermore, inflammatory conditions such as Crohn’s disease dramatically increase the risk of colorectal cancer (Balkwill et al., 2005; Balkwill and Mantovani, 2012; Coussens and Werb, 2002; Grivennikov et al., 2010).”
BackgroundImmunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · cited 4×
“Furthermore, inflammatory conditions such as Crohn’s disease dramatically increase the risk of colorectal cancer (Balkwill et al., 2005; Balkwill and Mantovani, 2012; Coussens and Werb, 2002; Grivennikov et al., 2010).”
BackgroundInfluentialMicroenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 3×
“…SPARC) that increases tumor cell-ECM interaction and thus migration (Sangaletti et al., 2008), Cathepsin proteases that remodel the matrix and release sequestered growth factors (Laoui et al., 2011; Quail and Joyce, 2013) and TGF-b that promotes EMT of the invading tumor cells (Bonde et al., 2012).”
BackgroundMolecular Mechanisms of Stress-Responsive Changes in Collagen and Elastin Networks in Skin
Aziz, J., Shezali, H., Radzi, Z., Yahya, N. A., Abu Kassim, N. H., Czernuszka, J., & Rahman, M. T. (2016) · Skin Pharmacology and Physiology · doi:10.1159/000447017 · Cited by 7,323
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753 · cited 1×
“TheseM-MDSCs have greater immunosuppressive potency than the granulocytic ones and are further defined as F4/80+ a marker also found on inflammatory monocytes (Gabrilovich and Nagaraj, 2009; Gabrilovich et al., 2012).”
BackgroundMacrophage plasticity and polarization: in vivo veritas
Sica, A., & Mantovani, A. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59643 · Cited by 6,335 · cited 2×
“References to these polarizing agents can be found in (De Palma and Lewis, 2013; Sica and Mantovani, 2012). above strongly support targeting the destruction or redifferentiation of macrophages as an important part of combinatorial therapies in human cancer patients.”
BackgroundAlternative activation of macrophages
Gordon, S. (2003) · Nature Reviews Immunology · doi:10.1038/nri978 · Cited by 6,189 · cited 1×
“…the activated macrophages responding to IFN-g, TNF-a, and Toll-like receptor 4 (TLR4) activation capable of killing pathogens through mechanisms such as iNOS, and (2) alternatively activated macrophages responding to IL-4 and IL-13 involved in antiparasitic immunity and in asthma (Gordon, 2003).”
BackgroundMacrophage Diversity Enhances Tumor Progression and Metastasis
Qian, B., & Pollard, J. W. (2010) · Cell · doi:10.1016/j.cell.2010.03.014 · Cited by 5,338 · cited 11×
“Furthermore, in most large-scale transcriptome analysis, macrophages have a mixed phenotype expressing both M1 and M2 markers (Qian and Pollard, 2010).”
BackgroundInfluentialSelf-citation
Flagged first, then by citations
2 of the 136 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Tumour-associated macrophages as treatment targets in oncology
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L., & Allavena, P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.217 · Cited by 4,157
Wound Healing: A Cellular Perspective
Rodrigues, M., Kosaric, N., Bonham, C. A., & Gurtner, G. C. (2018) · Physiological Reviews · doi:10.1152/physrev.00067.2017 · Cited by 3,211
Inflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 3,058
Murray, P. J. (2017) · Annual Review of Physiology · doi:10.1146/annurev-physiol-022516-034339 · Cited by 2,981
Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards
Bronte, V., Brandau, S., Chen, S.-H., Colombo, M. P., Frey, A. B., Greten, T. F., Mandruzzato, S., Murray, P. J., Ochoa, A., Ostrand-Rosenberg, S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12150 · Cited by 2,751
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
Costa-Silva, B., Aiello, N. M., Ocean, A. J., Singh, S., Zhang, H., Thakur, B. K., Becker, A., Hoshino, A., Mark, M. T., Molina, H., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3169 · Cited by 2,692
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications
Shibue, T., & Weinberg, R. A. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.44 · Cited by 2,539
Macrophages as regulators of tumour immunity and immunotherapy
DeNardo, D. G., & Ruffell, B. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0127-6 · Cited by 2,591
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Macrophages in immunoregulation and therapeutics
Chen, S., Saeed, A. F. U. H., Liu, Q., Jiang, Q., Xu, H., Xiao, G. G., Rao, L., & Duo, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01452-1 · Cited by 2,477
Roles of the immune system in cancer: From tumor initiation to metastatic progression
Gonzalez, H., Hagerling, C., & Werb, Z. (2018) · Genes & Development · doi:10.1101/gad.314617.118 · Cited by 2,111
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Targeting macrophages: therapeutic approaches in cancer
Cassetta, L., & Pollard, J. W. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.169 · Cited by 2,086
Self-citationTumor microenvironment as a therapeutic target in cancer
Xiao, Y. Q., & Yu, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 2,026
Neutrophils in cancer: Neutral no more
Coffelt, S. B., Wellenstein, M. D., & de Visser, K. E. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.52 · Cited by 1,830
Tumor-Associated Macrophages in Tumor Immunity
Pan, Y., Yu, Y., Wang, X., & Zhang, T. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583084 · Cited by 1,931
Böttcher, J. P., Bonavita, E., Chakravarty, P., Blees, H., Cabeza-Cabrerizo, M., Sammicheli, S., Rogers, N. C., Sahai, E., Zelenay, S., & Reis e Sousa, C. (2018) · Cell · doi:10.1016/j.cell.2018.01.004 · Cited by 1,857
Tumor microenvironment complexity and therapeutic implications at a glance
Baghban, R., Roshangar, L., Jahanban-Esfahlan, R., Seidi, K., Ebrahimi-Kalan, A., Jaymand, M., Kolahian, S., Javaheri, T., & Zare, P. (2020) · Cell Communication and Signaling · doi:10.1186/s12964-020-0530-4 · Cited by 1,784
“Accordingly, TAM-based therapeutic strategies are being developed that aim at TAM targeting, TAM reeducation, and TAM depletion [88, 96, 101, 102] .”
BackgroundMyeloid-derived suppressor cells coming of age
Veglia, F., Perego, M., & Gabrilovich, D. I. (2018) · Nature Immunology · doi:10.1038/s41590-017-0022-x · Cited by 1,818
The role of ROS in tumour development and progression
Cheung, E. C., & Vousden, K. H. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-021-00435-0 · Cited by 1,663
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589
Human chimeric antigen receptor macrophages for cancer immunotherapy
Klichinsky, M., Ruella, M., Shestova, O., Lu, X. M., Best, A., Zeeman, M., Schmierer, M., Gabrusiewicz, K., Anderson, N. R., Petty, N. E., et al. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0462-y · Cited by 1,495
Lin, Y., Xu, J., & Lan, H. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0760-3 · Cited by 1,398
Extracellular Vesicles: Unique Intercellular Delivery Vehicles
Maas, S. L. N., Breakefield, X. O., & Weaver, A. M. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.11.003 · Cited by 1,466
The Cancer Stem Cell Niche: How Essential Is the Niche in Regulating Stemness of Tumor Cells?
Plaks, V., Kong, N., & Werb, Z. (2015) · Cell Stem Cell · doi:10.1016/j.stem.2015.02.015 · Cited by 1,557
Macrophages and Therapeutic Resistance in Cancer
Ruffell, B., & Coussens, L. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.02.015 · Cited by 1,474
Cellular Senescence: Aging, Cancer, and Injury
Calcinotto, A., Kohli, J., Zagato, E., Pellegrini, L., Demaria, M., & Alimonti, A. (2019) · Physiological Reviews · doi:10.1152/physrev.00020.2018 · Cited by 1,270
Block copolymer micelles in nanomedicine applications
Cabral, H., Miyata, K., Osada, K., & Kataoka, K. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00199 · Cited by 1,309
Metabolism via Arginase or Nitric Oxide Synthase: Two Competing Arginine Pathways in Macrophages
Rath, M., ller, I. M. ⁄., Kropf, P., Closs, E. I., & Munder, M. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00532 · Cited by 1,332
Therapeutic developments in pancreatic cancer: current and future perspectives
Neoptolemos, J. P., Kleeff, J., Michl, P., Costello, E., Greenhalf, W., & Palmer, D. H. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0005-x · Cited by 1,170
Immune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
Self-citationTargeting Tumor Microenvironment for Cancer Therapy
Roma-Rodrigues, C., Mendes, R., Baptista, P. V., & Fernandes, A. R. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20040840 · Cited by 1,187
Tumor-associated macrophages: an accomplice in solid tumor progression
Chen, Y., Song, Y., Du, W., Gong, L., Chang, H., & Zou, Z. (2019) · Journal of Biomedical Science · doi:10.1186/s12929-019-0568-z · Cited by 1,096
Immunological hallmarks of stromal cells in the tumour microenvironment
Turley, S. J., Cremasco, V., & Astarita, J. L. (2015) · Nature Reviews Immunology · doi:10.1038/nri3902 · Cited by 1,140
Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer
Chung, W., Eum, H. H., Lee, H.-O., Lee, K.-M., Lee, H.-B., Kim, K.-T., Ryu, H. S., Kim, S., Lee, J. E., Park, Y. H., et al. (2017) · Nature Communications · doi:10.1038/ncomms15081 · Cited by 992
“Previous reports suggest that TAMs may show an immunosuppressive M2 signature, which promotes tumorigenesis by suppressing immune surveillance and inducing angiogenesis, rather than the activating M1-type signature 45 .”
InfluentialRadiotherapy and immunotherapy: a beneficial liaison?
Weichselbaum, R. R., Liang, H. L., Deng, L., & Fu, Y. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.211 · Cited by 1,091
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy
Gao, W., Wang, Y., Zhou, Y., Wang, X., & Yu, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01046-3 · Cited by 1,097
Klemm, F., Maas, R. R., Bowman, R. L., Kornete, M., Soukup, K., Nassiri, S., Brouland, J., Iacobuzio–Donahue, C. A., Brennan, C., Tabar, V. S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.05.007 · Cited by 1,030
CD8+ T cell differentiation and dysfunction in cancer
Philip, M., & Schietinger, A. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00574-3 · Cited by 1,052
Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
Cannarile, M. A., Weisser, M., Jacob, W., Jegg, A.-M., Ries, C. H., & Rüttinger, D. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0257-y · Cited by 1,046
An Immune Atlas of Clear Cell Renal Cell Carcinoma
Chevrier, S., Levine, J., Zanotelli, V. R., Siliņa, K., Schulz, D., Bacac, M., Ries, C. H., Ailles, L., Jewett, M. A. S., Moch, H., et al. (2017) · Cell · doi:10.1016/j.cell.2017.04.016 · Cited by 1,036
Developmental and Functional Heterogeneity of Monocytes
Guilliams, M., Mildner, A., & Yona, S. (2018) · Immunity · doi:10.1016/j.immuni.2018.10.005 · Cited by 973
Targeting tumor-associated macrophages in cancer
Pathria, P., Louis, T. L., & Varner, J. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.003 · Cited by 933
Şenbabaoğlu, Y., Gejman, R. S., Winer, A. G., Liu, M., Allen, E. M. V., de Velasco, G., Miao, D., Ostrovnaya, I., Drill, E. N., Luna, A., et al. (2016) · Genome biology · doi:10.1186/s13059-016-1092-z · Cited by 969
Macrophages: Development and Tissue Specialization
Varol, C., Mildner, A., & Jung, S. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112220 · Cited by 962
Dai, Y., Xu, C., Sun, X., & Chen, X. S. (2017) · Chemical Society Reviews · doi:10.1039/c6cs00592f · Cited by 939
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4195 · Cited by 833
The role of myeloid cells in cancer therapies
Engblom, C., Pfirschke, C., & Pittet, M. J. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.54 · Cited by 788
The Role of Cancer-Associated Fibroblasts and Fibrosis in Liver Cancer
Affo, S., Yu, L.-X., & Schwabe, R. F. (2017) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-052016-100322 · Cited by 757
Tumor-Associated Macrophages and Neutrophils in Tumor Microenvironment
Kim, J., & Bae, J. (2016) · Mediators of Inflammation · doi:10.1155/2016/6058147 · Cited by 820
Zhu, Y., Herndon, J. M., Sojka, D. K., Kim, K.-W., Knolhoff, B. L., Zuo, C., Cullinan, D. R., Luo, J. R., Bearden, A. R., Lavine, K. J., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.07.014 · Cited by 828
Obesity, Inflammation, and Cancer
Deng, T., Lyon, C. J., Bergin, S. M., Caligiuri, M. A., & Hsueh, W. A. (2016) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012615-044359 · Cited by 831
Dynamic EMT: a multi‐tool for tumor progression
Brabletz, S., Schuhwerk, H., Brabletz, T., & Stemmler, M. P. (2021) · The EMBO Journal · doi:10.15252/embj.2021108647 · Cited by 800
Genetics and biology of prostate cancerPreprint
Wang, G., Zhao, D., Spring, D. J., & DePinho, R. A. (2018) · Genes & Development · doi:10.1101/gad.315739.118 · Cited by 814
Schietinger, A., Philip, M., Krisnawan, V. E., Chiu, E. Y., Delrow, J. J., Basom, R. S., Lauer, P., Brockstedt, D. G., Knoblaugh, S. E., Hämmerling, G. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.07.011 · Cited by 720
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani‐Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 782
Li, X., Yao, W., Yuan, Y., Chen, P., Li, B., Li, J., Chu, R., Song, H., Xie, D., Jiang, X., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-310514 · Cited by 739
Role of Bruton’s tyrosine kinase in B cells and malignancies
Pal Singh, S., Dammeijer, F., & Hendriks, R. W. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0779-z · Cited by 726
New horizons in tumor microenvironment biology: challenges and opportunities
Chen, F., Zhuang, X., Lin, L., Yu, P., Wang, Y., Shi, Y., Hu, G., & Sun, Y. (2015) · BMC Medicine · doi:10.1186/s12916-015-0278-7 · Cited by 704
Liposomes Coated with Isolated Macrophage Membrane Can Target Lung Metastasis of Breast Cancer
Cao, H., Dan, Z., He, X., Zhang, Z., Yu, H., Yin, Q., & Li, Y. (2016) · ACS Nano · doi:10.1021/acsnano.6b03148 · Cited by 697
Macrophages and cancer: from mechanisms to therapeutic implications
Ostuni, R., Kratochvill, F., Murray, P. J., & Natoli, G. (2015) · Trends in Immunology · doi:10.1016/j.it.2015.02.004 · Cited by 709
Type 2 cytokines: mechanisms and therapeutic strategies
Wynn, T. A. (2015) · Nature reviews. Immunology · doi:10.1038/nri3831 · Cited by 683
CXCL9:SPP1 macrophage polarity identifies a network of cellular programs that control human cancers
Bill, R., Wirapati, P., Messemaker, M., Roh, W., Zitti, B., Duval, F., Kiss, M., Park, J. C., Saal, T. M., Hoelzl, J., et al. (2023) · Science · doi:10.1126/science.ade2292 · Cited by 698
mTORC2-IRF4 mediated metabolic reprograming is essential for macrophage alternative activation
Huang, S., Smith, A., Everts, B., Colonna, M., Pearce, E. L., Schilling, J., & Pearce, E. J. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.016 · Cited by 579
Arlauckas, S. P., Garris, C. S., Kohler, R. H., Kitaoka, M., Cuccarese, M. F., Yang, K. S., Miller, M. A., Carlson, J. C., Freeman, G. J., Anthony, R. M., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3604 · Cited by 669
Fares, C. M., Allen, E. M. V., Drake, C. G., Allison, J. P., & Hu‐Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 665
Georgoudaki, A.-M., Prokopec, K. E., Boura, V. F., Hellqvist, E., Sohn, S., Östling, J., Dahan, R., Harris, R. A., Rantalainen, M., Klevebring, D., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.04.084 · Cited by 609
Tissue biology perspective on macrophages
Okabe, Y., & Medzhitov, R. M. (2015) · Nature Immunology · doi:10.1038/ni.3320 · Cited by 651
Targeting macrophages in cancer immunotherapy
Duan, Z., & Luo, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00506-6 · Cited by 656
Zheng, P., Chen, L., Yuan, X., Luo, Q., Liu, Y., Xie, G., Ma, Y., & Shen, L. (2017) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-017-0528-y · Cited by 637
The immunological and metabolic landscape in primary and metastatic liver cancer
Li, X., Ramadori, P., Pfister, D. R., Seehawer, M., Zender, L., & Heikenwälder, M. F. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00383-9 · Cited by 639
The interaction of anticancer therapies with tumor-associated macrophages
Mantovani, A., & Allavena, P. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20150295 · Cited by 634
Ali, H. R., Chlon, L., Pharoah, P. D. P., Markowetz, F. M., & Caldas, C. (2016) · PLoS Medicine · doi:10.1371/journal.pmed.1002194 · Cited by 619
Alspach, E., Lussier, D. M., & Schreiber, R. D. (2018) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a028480 · Cited by 638
Key chemokines direct migration of immune cells in solid tumors
Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00303-x · Cited by 583
The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
Petitprez, F., Meylan, M., de Reyniès, A., Sautès‐Fridman, C., & Fridman, W. H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00784 · Cited by 621
Consensus guidelines for the use and interpretation of angiogenesis assays
Nowak-Sliwinska, P. M., Alitalo, K. K., Allen, E., Anisimov, A., Aplin, A. C., Auerbach, R., Augustin, H. G., Bates, D. O., B, J. R. V. B., Bender, R. H. F., et al. (2018) · Angiogenesis · doi:10.1007/s10456-018-9613-x · Cited by 619
Self-citationSaha, D., Martuza, R. L., & Rabkin, S. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.006 · Cited by 593
Monocyte heterogeneity and functions in cancer
Olingy, C. E., Dinh, H. Q., & Hedrick, C. C. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.4ri0818-311r · Cited by 598
Wang, S., Wang, J., Chen, Z., Luo, J., Guo, W., Sun, L., & Lin, L. (2024) · npj Precision Oncology · doi:10.1038/s41698-024-00522-z · Cited by 657
“129 in their highly cited review on the therapeutic mechanism of TAM also mention that TAMs express PD-L1 and Cytotoxic T-lymphocyte-associated antigen (CTLA) − 4 ligands, which block the T lymphocytes ’ adaptive immune response and reduce the anticancer effects…”
Ugel, S., Sanctis, F. D., Mandruzzato, S., & Bronte, V. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80006 · Cited by 574
Ginseng-derived nanoparticles alter macrophage polarization to inhibit melanoma growth
Cao, M., Yan, H., Han, X., Weng, L., Qin, W. D., Sun, X., Lu, W., Wei, Q., Ye, J., Cai, X., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0817-4 · Cited by 571
Ushach, I., & Zlotnik, A. (2016) · Journal of Leukocyte Biology · doi:10.1189/jlb.3ru0316-144r · Cited by 551
Wang, J., & Kubes, P. (2016) · Cell · doi:10.1016/j.cell.2016.03.009 · Cited by 537
Adaptive plasticity of IL-10+ and IL-35+ Treg cells cooperatively promotes tumor T cell exhaustion
Sawant, D. V., Yano, H., Chikina, M. D., Zhang, Q., Liao, M., Liu, C., Callahan, D. J., Sun, Z., Sun, T., Tabib, T., et al. (2019) · Nature Immunology · doi:10.1038/s41590-019-0346-9 · Cited by 569
Macrophage Polarization in Chronic Inflammatory Diseases: Killers or Builders?
Parisi, L., Gini, E., Baci, D., Tremolati, M., Fanuli, M., Bassani, B., Farronato, G., Bruno, A., & Mortara, L. (2018) · Journal of Immunology Research · doi:10.1155/2018/8917804 · Cited by 508
The Biology of Cancer Exosomes: Insights and New Perspectives
Ruivo, C. F., Adem, B., Silva, M. G., & Melo, S. A. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0994 · Cited by 547
The hypoxic tumor microenvironment: A driving force for breast cancer progression
Semenza, G. L. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.05.036 · Cited by 535
A history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0006-7 · Cited by 502
Aspects of the Tumor Microenvironment Involved in Immune Resistance and Drug Resistance
Khalaf, K., Hana, D., Chou, J. T.-T., Singh, C., Mackiewicz, A. A., & Kaczmarek, M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.656364 · Cited by 551
Perivascular M2 Macrophages Stimulate Tumor Relapse after Chemotherapy
Hughes, R., Qian, B., Rowan, C., Muthana, M., Keklikoglou, I., Olson, O. C., Tazzyman, S. J., Danson, S. J., Addison, C., Clemons, M. J., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3587 · Cited by 516
Self-citationControl of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39
Takenaka, M. C., Gabriely, G., Rothhammer, V., Mascanfroni, I. D., Wheeler, M. A., Chao, C.-C., Gutiérrez-Vázquez, C., Kenison, J., Tjon, E. C., Barroso, A., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0370-y · Cited by 517
Genetically engineered mouse models in oncology research and cancer medicine
Kersten, K., de Visser, K. E., van Miltenburg, M. H., & Jonkers, J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201606857 · Cited by 502
Chen, D., Xie, J., Fiskesund, R., Dong, W., Liang, X., Lv, J., Jin, X., Liu, J., Mo, S., Zhang, T., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03225-9 · Cited by 489
Membrane Cholesterol Efflux Drives Tumor-Associated Macrophage Reprogramming and Tumor Progression
Goossens, P., Rodriguez-Vita, J., Etzerodt, A., Masse, M., Rastoin, O., Gouirand, V., Ulas, T., Papantonopoulou, O., Van Eck, M., Auphan-Anezin, N., et al. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.02.016 · Cited by 502
Lipids in the tumor microenvironment: From cancer progression to treatment
Corn, K. C., Windham, M. A., & Rafat, M. (2020) · Progress in Lipid Research · doi:10.1016/j.plipres.2020.101055 · Cited by 486
A fate worse than death: apoptosis as an oncogenic process
Ichim, G., & Tait, S. W. G. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.58 · Cited by 451
Biomaterial-assisted targeted modulation of immune cells in cancer treatment
Wang, H., & Mooney, D. J. (2018) · Nature Materials · doi:10.1038/s41563-018-0147-9 · Cited by 473
Chen, Y., Yin, J., Li, W., Li, H.-J., Chen, D., Zhang, C., Lv, J., Wang, Y., Li, X., Li, J., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0374-x · Cited by 478
Oncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 510
Metadata
- Authors
- Noy, R., & Pollard, J. W.
- Affiliations
- Albert Einstein College of Medicine (US)
- Corresponding author
- Pollard, Jeffrey W.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2014-07
- Volume
- 41
- Issue
- 1
- Pages
- 49-61
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC4137410
- OpenAlex
- W1971620413
- Cited by
- 4,089
- References
- 136
- Citations by year
- 2026: 258 · 2025: 326 · 2024: 359 · 2023: 393 · 2022: 485 · 2021: 479 · 2020: 424 · 2019: 379 · 2018: 297 · 2017: 285 · 2016: 215 · 2015: 157 · 2014: 27
- FWCI
- 22.25
- Type
- journal article
- Language
- en
- Update notices
- erratum (2014-11-20)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Wellcome Trust (101067, 101067/Z/13/Z)
- National Institutes of Health (UL1TR001073)
- National Cancer Institute (P01CA100324, R01CA172451)
- National Center for Advancing Translational Sciences
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- tumor-associated macrophages, tumor microenvironment, tumor angiogenesis, tumor invasion, metastasis, pre-metastatic niche, immunosuppression, natural killer cells, T cells, macrophage-targeted therapy, combination cancer therapy
- MeSH terms
- Animals, Cell Movement, Cell Survival, Cell Transformation, Neoplastic, Humans, Immunosuppression Therapy, Macrophages, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Cell Lineage, Cell Proliferation, Mice, Tumor Microenvironment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
